Energized Biogen Idec On Track For Two Filings In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.